Clinical Trials
For Investigators, Industry, & Government Entities
Considering UT Health San Antonio for a clinical trial site? Complete the clinical trials online form (will take 5 - 8 minutes) to start the conversation with one of our navigators.
Institutional Core Labs
- iLabs
- Bioanalytics & Single-Cell
- Biospecimen and Translational Genomics
- Flow Cytometry
- Mass Spectometry
- Optical Imaging
- Structural Biology (NMR)
- Structural Biology (X-Ray Crystallography)
Find a Researcher
Research by School
Software Training & Cyberinfrastructure
Additional Resources
Reasons to partner with us
-
UT Health Physicians have over 100 specialties and subspecialties with 1.6 million patient visits per year at 16 clinics.
-
The Mays Cancer Center is home to the world-renowned Institute for Drug Development (IDD) where many of the most commonly used FDA-approved anticancer drugs were developed. At any given time, the IDD is testing as many as 60 new drugs and drug combinations and has over 180 clinical trials open for patient enrollment.
-
UT Dentistry offers 9 specialty clinics staffed by more than 100 faculty experts.
-
For over a decade, the Association for the Accreditation of Human Research Protection Programs (AAHRPP) has recognized the ethical and effcient operations of our clinical research program.
-
As a Clinical and Translational Science Award (CTSA) hub, we emphasize the importance of accelerating the research process to translate scientific discovery and offer a master IRB reliance agreement through a SMART IRB platform expediting the regulatory approval process for multisite studies.
-
San Antonio is the largest minority-majority city in the United States and is home to 7 military installations comprising a large active-duty and retired military population with unique needs.
-
Through multi-modal strategies, we aim to bring more awareness to our communities about their role in clinical trials.
Contact us
Clinical Trials Office (CTO)
Jason Bates, MBA
210-450-8532
vprcto@uthscsa.edu
Mays Cancer Center Clinical Trials Office
Cindy McKeown, RN, BSN, MPA
210-450-1286
ctofinance@uthscsa
-
$6,638,575
industry clinical trial revenue in 2020
-
Over 170
actively recruiting cancer trials
-
20
institutes and centers with diverse research specialities
Innovation Highlight
UT Health San Antonio is a COVID-19 vaccine study site
Dr. Barbara Taylor is leading a COVID-19 research team conducting a clinical trial evaluating an investigational vaccine to see if it helps prevent COVID-19.
Advancing Commercialization
Collaborating to produce low-cost ventilators
UT Health San Antonio researchers are collaborating with a team from The University of Texas at Austin to build a new type of ventilator made of inexpensive, widely available materials to help fill the demand created by the spread of COVID-19 for these critical devices that help patients breathe.
“Partnering with industry has allowed me to advance my clinical research skills and provide my patients cutting-edge treatment options and excellent care. Being an academic health center, clinical trials distinguish us as global leaders conducting groundbreaking multi-center studies like CREDENCE, SONAR, and the Trial Innovative Network study SPIRRIT-HF. The SONAR trial became one of the top recruitment sites out of 689 participating sites across 41 countries. This trend continues as we exemplify patient enrollment practices for diabetes, kidney, and metabolic disorders.”
Shweta Bansal, M.D., associate professor of medicine and program director of the Nephrology Fellowship Program at UT Health San Antonio
Spotlight
-
Pilot study aims to improve diet patterns in Asian Americans with diabetes
Dr. Jisook Ko, assistant professor in the School of Nursing, who is a scientist of the Asian Resource Center for Minority Aging Research supported by the National Institute on Aging was selected to receive a pilot grant of $34,920.
-
Study will compare 2 treatment strategies for severe brain injury; public comment requested
A study of emergency care involving victims of severe brain trauma is to be performed in the San Antonio area. The study will include adults and children older than 14 years with severe brain injury requiring admission to the ICU with brain monitoring. Hospitals across the country are conducting the study, which is funded by the U.S. National Institutes of Health.
-
New Drug Approved for Treating Rare Blood Cancer
Dr. Ruben Mesa was part of the international research team that led the development and approval of fedratinib, becoming the 2nd drug that can be used to treat myelofibrosis, after huge success in Phase 3 trial, JAKARTA.